Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;47(1):108-126.
doi: 10.1111/nan.12645. Epub 2020 Aug 17.

Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics

J K Petersen  1   2 , H B Boldt  1   2 , M D Sørensen  1   2 , S Blach  1 , R H Dahlrot  2   3 , S Hansen  2   3 , M Burton  4 , M Thomassen  2   4 , T Kruse  2   4 , F R Poulsen  2   5 , L Andreasen  6 , H Hager  6 , B P Ulhøi  7 , S Lukacova  8 , G Reifenberger  9   10 , B W Kristensen  1   2
Affiliations

Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics

J K Petersen et al. Neuropathol Appl Neurobiol. 2021 Feb.

Abstract

Aims: We aimed to reclassify a population-based cohort of 529 adult glioma patients to evaluate the prognostic impact of the 2016 World Health Organization (WHO) central nervous system tumour classification. Moreover, we evaluated the feasibility of gene panel next-generation sequencing (NGS) in daily diagnostics of 225 prospective glioma patients.

Methods: The retrospective cohort was reclassified according to WHO 2016 criteria by immunohistochemistry for IDH-R132H, fluorescence in situ hybridization for 1p/19q-codeletion and gene panel NGS. All tumours of the prospective cohort were subjected to NGS analysis up-front.

Results: The entire population-based cohort was successfully reclassified according to WHO 2016 criteria. NGS results were obtained for 98% of the prospective patients. Survival analyses in the population-based cohort confirmed three major prognostic subgroups, that is, isocitrate dehydrogenase (IDH)-mutant and 1p/19q-codeleted oligodendrogliomas, IDH-mutant astrocytomas and IDH-wildtype glioblastomas. The distinction between WHO grade II and III was prognostic in patients with IDH-mutant astrocytoma. The survival of patients with IDH-wildtype diffuse astrocytomas carrying TERT promoter mutation and/or EGFR amplification overlapped with the poor survival of IDH-wildtype glioblastoma patients.

Conclusions: Gene panel NGS proved feasible in daily diagnostics. In addition, our study confirms the prognostic role of glioma classification according to WHO 2016 in a large population-based cohort. Molecular features of glioblastoma in IDH-wildtype diffuse glioma were linked to poor survival corresponding to IDH-wildtype glioblastoma patients. The distinction between WHO grade II and III retained prognostic significance in patients with IDH-mutant diffuse astrocytic gliomas.

Keywords: Gliomas; cIMPACT-NOW; mutational profiles; prognostic evaluation; reclassification; targeted next-generation sequencing (NGS).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Carter JH, McNulty SN, Cimino PJ, Cottrell CE, Heusel JW, Vigh-Conrad KA, et al. Targeted next-generation sequencing in molecular subtyping of lower-grade diffuse gliomas: application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors. J Mol Diagn 2017; 19: 328-37
    1. von Deimling A, Ono T, Shirahata M, Louis D. Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing. Semin Neurol 2018; 38: 19-23
    1. Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, et al. Retrospective analysis of molecular and immunohistochemical characterization of 381 primary brain tumors. J Neuropathol Exp Neurol 2017; 76: 179-88
    1. Nikiforova MN, Wald AI, Melan MA, Roy S, Zhong S, Hamilton RL, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol 2016; 18: 379-87
    1. Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol 2016; 131: 903-10

Publication types

MeSH terms